The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 260 participants.
Also called NCT07120828
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 260 participants
- Sponsor
- Erbil Polytechnic University
- Registry
-
NCT07120828
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Iraq
- Registry status
- Completed
Technical summary
Registry record NCT07120828. Randomized; no masking; primary purpose treatment. Start 2025-07-15 (actual); primary completion 2025-08-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
- Acronym
- CYP8B1-SGLT2-T
- Condition
- Type 2 Diabetes
- Condition
- Obese Diabetics
- Condition
- Obese Patients (BMI ≥ 30 kg/m²)
- Intervention (Drug)
- Empagliflozin (oral)
- Intervention (Drug)
- Dapagliflozin (DAPA)
- Intervention (Drug)
- Metfomin
- Lead sponsor
- Erbil Polytechnic University
- Collaborator
- Kurdistan Higher Council of Medical Specialties
Record details
- Record id
cardio:ct-nct07120828- Content hash
ba48a2de53c50cd48bc8d384131434b75b52a10d59daf47a47a7bcf0f6715345